Assembly Biosciences, Inc. (ASMB) Return on equity 2016–2025
Assembly Biosciences, Inc. (ASMB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-3.0%FY2025 · since FY2016: -55.4% → -3.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -3.0% | +117.5 pp |
| FY2024 | -120.4% | +28.5 pp |
| FY2023 | -149.0% | -36.4 pp |
| FY2022 | -112.6% | -35.7 pp |
| FY2021 | -76.9% | -51.0 pp |
| FY2020 | -25.8% | +9.9 pp |
| FY2019 | -35.7% | +7.3 pp |
| FY2018 | -43.1% | -5.2 pp |
| FY2017 | -37.8% | +17.6 pp |
| FY2016 | -55.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ASMB financial trends
ASMB RevenueASMB Net incomeASMB Net marginASMB Gross profitASMB Gross marginASMB Operating incomeASMB Operating marginASMB Operating cash flowASMB Free cash flowASMB Capital expendituresASMB Stock buybacksASMB Dividends paidASMB Total assetsASMB Total liabilitiesASMB Shareholders’ equityASMB overview →